TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3288460

Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine daily intravenously for a mean of 3.9 days
Number of subjects: 400

Group type: COMPARATOR
Intervention: 200 mg ranitidine daily intravenously for a mean of 3.9 days
Number of subjects: 400

Group type: COMPARATOR
Intervention: 200 mg ranitidine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine
Number of subjects: 400
Study: 30683061

Group type: EXPERIMENTAL
Intervention: Garlic extract (400 mg twice a day for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28424871

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab
Number of subjects: 170

Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 170
Study: 26563012

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg), administered once daily for 2 days and tapered down, completed on day 10
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg)
Number of subjects: 65
Study: 23308174

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 ug/kg single dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Filgrastim (5 ug/kg/day for 9 doses)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 61
Study: 21657939

Group type: EXPERIMENTAL
Intervention: Suture reinforcement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Seamguard reinforcement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fibrin glue (excluded from analysis)
Number of subjects: 20
Study: 18834464

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 66
Study: 16440209

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEO) 0.625 mg daily
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 14514742

Group type: EXPERIMENTAL
Intervention: Bicarbonate PD fluid (34 mM pure bicarbonate at neutral pH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lactate PD fluid (35 mM lactate)
Number of subjects: 28
Study: 10962221

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine added to fluphenazine decanoate and benztropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-hoc analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant medication
Number of subjects: 0
Study: 8793416

Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fatty acids (PUFA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SAFA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Diet rich in SAFA
Number of subjects: 75
Study: 1613811

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 0
Study: 6488704

Group type: EXPERIMENTAL
Intervention: Low tar cigarette with nicotine yield of 0.55 mg (LN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low tar cigarette with nicotine yield of 0.90 mg (MN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Usual brand cigarette
Number of subjects: 9

Group type: COMPARATOR
Intervention: All cigarette types
Number of subjects: 9
Study: 30269876

Group type: EXPERIMENTAL
Intervention: RFM care package intervention
Number of subjects: 409175

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 409175
Study: 27841024

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MI-Exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heavy-Intensity Exercise (HI-Exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 11
Study: 24824051

Group type: EXPERIMENTAL
Intervention: Pre-treatment snack with education messages
Number of subjects: 1284

Group type: COMPARATOR
Intervention: Education messages alone (Control)
Number of subjects: 1284
Study: 22298552

Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Delton Plus FS+)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GC Fuji Triage White)
Number of subjects: 39
Study: 20956409

Group type: EXPERIMENTAL
Intervention: Prenatal corticosteroid therapy
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2104
Study: 18942420

Group type: EXPERIMENTAL
Intervention: Viferon
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 15329600

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.09, 0.24, 0.54, and 1.23 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfentanil (13.4, 33.8, 67.8, and 126.1 ng/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12038744

Group type: EXPERIMENTAL
Intervention: Community-based participatory research approach
Number of subjects: 0
Study: 9641851

Group type: EXPERIMENTAL
Intervention: Experimental group (30 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group (9 patients with EMG+ response)
Number of subjects: 40
Study: 7982345

Group type: EXPERIMENTAL
Intervention: Conventional methods of positive-pressure ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluid and hemodynamic support strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer pharmacologic agents
Number of subjects: 0
Study: 2518989

Group type: EXPERIMENTAL
Intervention: Educational counselling to lose weight, hypocaloric diet, and motivational support; followed for a mean period of 239 days.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual types of management (control group).
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Experimental group (educational counselling).
Number of subjects: 155
Study: 326641

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 29603130

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - home-based program using a flow-resistive inspiratory loading device, training twice a day at high intensity for 2 weeks or longer until surgery
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 241
Study: 26943711

Group type: EXPERIMENTAL
Intervention: Weekday sleep debt
Number of subjects: 593
Study: 24899130

Group type: EXPERIMENTAL
Intervention: Composite graft (bioactive porous Poly dl-lactide-co-glycolide scaffolds with antibiotic gentamicin and crosslinked gelatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite graft
Number of subjects: 0
Study: 22237870

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula with 10(6) CFU Bb12/g (PRO)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Partially hydrolyzed whey formula (CON)
Number of subjects: 172
Study: 20737608

Group type: EXPERIMENTAL
Intervention: GSM (Global System for Mobile Communications, 900 MHz and 1,800 MHz) base station signals
Number of subjects: 397

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 397
Study: 18423901

Group type: EXPERIMENTAL
Intervention: Unobserved dosing
Number of subjects: 119

Group type: COMPARATOR
Intervention: Observed dosing
Number of subjects: 119
Study: 15746667

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg initially followed by 100 microg in each subsequent dose)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 microg in each dose)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 204
Study: 12933402

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.1 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2 micro g/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 43
Study: 11103227

Group type: EXPERIMENTAL
Intervention: Tofu (290 g daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Meat (150 g lean meat daily)
Number of subjects: 42
Study: 8624148

Group type: EXPERIMENTAL
Intervention: Topical 0.1% tretinoin cream
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 22
Study: 1728202

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 24
Study: 6700383

Group type: EXPERIMENTAL
Intervention: Thrice weekly intra‐muscular injections of 7.5 to 10 megaunits of interferon/m2
Number of subjects: 6

Group type: COMPARATOR
Intervention: Daily injections of interferon
Number of subjects: 6
Study: 31813508

Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR)
Number of subjects: 657
Study: 30394493

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy, mean duration 10.1±3.9 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 38
Study: 26856289

Group type: EXPERIMENTAL
Intervention: Colgate Optic White WT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Crest Pro‐Health Whitening WT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Arm and Hammer Advance White Extreme Whitening WT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (brushed with water without WT)
Number of subjects: 80
Study: 24910196

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemic waist phenotype
Number of subjects: 517
Study: 22929964

Group type: EXPERIMENTAL
Intervention: Green tea extract (250 or 500 ml of a milk whey based green tea containing soft drink)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Milk whey based soft drink without green tea (control)
Number of subjects: 12
Study: 20042421

Group type: EXPERIMENTAL
Intervention: 4D AutoLVQ software
Number of subjects: 103
Study: 17563741

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with marrow purged with 4 hydroperoxycyclophosphamide
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intensive timed induction therapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 137
Study: 15649852

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 microg bid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Theophylline (orally dose titrated slow‐release)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11803253

Group type: EXPERIMENTAL
Intervention: Vapor-permeable article
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vapor-impermeable article
Number of subjects: 0
Study: 9951784

Group type: EXPERIMENTAL
Intervention: Calcium and calcitriol supplements
Number of subjects: 49

Group type: COMPARATOR
Intervention: No supplements
Number of subjects: 49
Study: 7762059

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Prednisone (Pred) with Pred withdrawal
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conversion from CsA to Azathioprine (Aza-Pred)
Number of subjects: 120
Study: 3297230

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oxycone-papaverine (5 mg + 50 mg)
Number of subjects: 61
Study: 31689141

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (TM-group) with follow-up every 3 months and monthly telemedicine support.
Number of subjects: 483

Group type: COMPARATOR
Intervention: 3-month follow-up (3M-group).
Number of subjects: 483

Group type: COMPARATOR
Intervention: 1-month follow-up (1M-group).
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: TM-group and 1M-group patients with poor adherence at baseline.
Number of subjects: 483

Group type: COMPARATOR
Intervention: 3M-group patients with poor adherence at baseline.
Number of subjects: 483
Study: 30541634

Group type: EXPERIMENTAL
Intervention: Decision aid (evidence-based decision aid about mammography screening)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Active control (information about home safety)
Number of subjects: 426
Study: 27595728

Group type: EXPERIMENTAL
Intervention: 5% EMLA cream
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Local pressure
Number of subjects: 140

Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 26583142

Group type: EXPERIMENTAL
Intervention: Crossover training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stabilometric platform training
Number of subjects: 60
Study: 23559150

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20951147

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no risedronate)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5mg/day) and Control
Number of subjects: 63
Study: 19058068

Group type: EXPERIMENTAL
Intervention: Ovarian cancer psychoeducational intervention (OCPI) - 4 sequential, structured, in-person educational sessions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 20562702

Group type: EXPERIMENTAL
Intervention: TAK-242 1.2 mg/kg/day
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: TAK-242 2.4 mg/kg/day
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 15684116

Group type: EXPERIMENTAL
Intervention: Amoxicillin (60 mg/kg daily for 10 days)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Amoxicillin and Placebo
Number of subjects: 512
Study: 11925355

Group type: EXPERIMENTAL
Intervention: 100 microg of thyroxine daily
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 9426384

Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat area of the fourth scan (L2-L3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat area of the third scan (L1-L2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat areas of the sixth and seventh scans (L4-L5)
Number of subjects: 23
Study: 7895394

Group type: EXPERIMENTAL
Intervention: Supervised training twice a week for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home training after 2 hours of instruction
Number of subjects: 40
Study: 3075410

Group type: EXPERIMENTAL
Intervention: 10 mg of tripamide
Number of subjects: 159

Group type: COMPARATOR
Intervention: 50 mg of hydrochlorothiazide
Number of subjects: 159
Study: 11307810

Group type: EXPERIMENTAL
Intervention: Argatroban (1-2 microg/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Argatroban (higher doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Co-therapy (argatroban and warfarin)
Number of subjects: 24
Study: 31048415

Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 30172765

Group type: EXPERIMENTAL
Intervention: Surgical navigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no surgical navigation)
Number of subjects: 20
Study: 27212102

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 74

Group type: COMPARATOR
Intervention: No resurfacing
Number of subjects: 74
Study: 25416486

Group type: EXPERIMENTAL
Intervention: In-home counselling intervention using the APN-BQ Instrument
Number of subjects: 206
Study: 23075570

Group type: EXPERIMENTAL
Intervention: Early discharge from hospital after 3 days inpatient treatment with home visits by generic community nurses
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 139
Study: 19858233

Group type: EXPERIMENTAL
Intervention: Combination of eight biomarkers (von Willebrand factor antigen, surfactant protein D, tumor necrosis factor receptor‐1, interleukin [IL]‐6, IL‐8, intercellular adhesion molecule‐1, protein C, plasminogen activator inhibitor‐1) and clinical predictors (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Clinical predictors alone (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Best performing biomarkers (neutrophil chemotactic factor, IL‐8, and surfactant protein D)
Number of subjects: 549
Study: 17885562

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg daily
Number of subjects: 382

Group type: COMPARATOR
Intervention: Nitrendipine 20 mg twice daily
Number of subjects: 382
Study: 15699722

Group type: EXPERIMENTAL
Intervention: Meniett device treatment (pressure pulses at 6 Hz for 0.6 seconds, oscillating between 0.4 and 1.2 kPa)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meniett device treatment
Number of subjects: 40
Study: 12084604

Group type: EXPERIMENTAL
Intervention: Biventricular CRT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Univentricular CRT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: First treatment (both methods pooled)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Second treatment (both methods pooled)
Number of subjects: 41
Study: 9700176

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 64
Study: 7638950

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (1 mg) with metoclopramide (10 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diclofenac (75 mg) with metoclopramide (10 mg)
Number of subjects: 34
Study: 2495710

Group type: EXPERIMENTAL
Intervention: Flecainide (1 mg/kg bolus over 10 minutes followed by 1.5 mg/kg/hr for 1 hour and then 0.25 mg/kg/hr for 24 hours)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Digoxin (3 bolus doses: 0.5 mg followed after 6 and 12 hours by 0.25 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 29
Study: 972015

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy started within two months of oophorectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy started after three years post-oophorectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed estrogen replacement therapy started after six years post-oophorectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients post-oophorectomy
Number of subjects: 0
Study: 30653528

Group type: EXPERIMENTAL
Intervention: High construal level condition combined with high social distance condition
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: High construal level with high social distance
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Combination of two high construal level approaches
Number of subjects: 197
Study: 28705454

Group type: COMPARATOR
Intervention: 15 mg/kg ATLG
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 30 mg/kg ATLG
Number of subjects: 175
Study: 25226850

Group type: EXPERIMENTAL
Intervention: QAX576 (6 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24429201

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor or H2 blocker
Number of subjects: 242

Group type: COMPARATOR
Intervention: No anti-acid treatment
Number of subjects: 242
Study: 21729174

Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected intradermally)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected subdermally)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.1 mL injected subcutaneously)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Histopathology on day 7 from 22 reactions in 15 patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prick test vs. histamine reference
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Measurement of circulating insulin detemir‐specific antibodies by RIA before and after 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Saline injection)
Number of subjects: 40
Study: 19555936

Group type: EXPERIMENTAL
Intervention: Olive oil (60 mL) followed by 2 L of PEG-ELS (Prep 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (15 g) followed by 2 L of PEG-ELS (Prep 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional volume (4 L) of PEG-ELS (Prep 1)
Number of subjects: 120
Study: 17145603

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral chlorambucil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous or allogeneic stem cell transplantation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fludarabine-containing regimens
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Schedules including non-cross-reactive agents, such as alemtuzumab
Number of subjects: 8
Study: 12932242

Group type: EXPERIMENTAL
Intervention: 1% coal tar preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcipotriol cream
Number of subjects: 40
Study: 10804813

Group type: EXPERIMENTAL
Intervention: Localized skeletal muscle training (unilateral calf plantar flexion exercise)
Number of subjects: 7
Study: 8653439

Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) with added fortifier
Number of subjects: 22

Group type: COMPARATOR
Intervention: Expressed breast milk (EBM) alone
Number of subjects: 22
Study: 2071723

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Amitriptyline therapy (25, 50, or 75 mg/day)
Number of subjects: 41
Study: 6318346

Group type: EXPERIMENTAL
Intervention: Bi‐Profenid tablets (300 mg in 2 daily oral doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Profenid capsules (300 mg in 3 daily oral doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Profenid capsules
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bi‐Profenid tablets
Number of subjects: 43
Study: 30904207

Group type: EXPERIMENTAL
Intervention: Almonds (AS: 56 g/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Biscuit snack (BS)
Number of subjects: 76